Mucociliary Clearance Clinical Trial
Official title:
Mucociliary Clearance in Healthy Subjects: Comparison of Levalbuterol and Racemic Albuterol
The purpose of this study is to determine whether lung mucociliary clearance (MCC) can be significantly enhanced in healthy subjects by one week of inhalation of nebulized levalbuterol aerosol, as compared to racemic albuterol or placebo. Subjects will inhale one week of levalbuterol, one week of racemic albuterol, and one week of placebo, in a randomized order.
In healthy lungs, inhaled insoluble material such as bacteria, viruses, antigens, and toxins
deposit in the tracheobronchial airway mucus and are removed from the lung in a matter of
hours by mucociliary clearance (MCC). When MCC is overwhelmed or impaired, some mucus can be
removed by mechanical or cough clearance (CC). Impairment of MCC typically leads to the
accumulation of mucus in the airways, and this in turn is associated with acute infections,
chronic bacterial colonization, and chronic inflammation.
Racemic albuterol has been shown to stimulate MCC in various patient populations. Inhaled
and subcutaneous terbutaline has also been shown to stimulate MCC in healthy subjects. We
hypothesize that levalbuterol will be more potent than racemic albuterol in enhancing MCC
and CC in healthy subjects.
;
Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Treatment
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT00951522 -
A Trial to Assess the Safety, Tolerability, and Pharmacokinetics of GS-9411 in Healthy Male Volunteers
|
Phase 1 | |
| Completed |
NCT00999531 -
A Randomized, Double-Blind, Placebo-Controlled Multiple Dose Trial of GS-9411 in Healthy Volunteers
|
Phase 1 | |
| Completed |
NCT00902707 -
Evaluating the Effect of Mucinex® 1200 mg on Mucociliary and Cough Clearance From the Human Lung
|
Phase 1 | |
| Completed |
NCT05875025 -
Study to Assess the Effect of the New HFA-152a Propellant on Mucociliary Clearance
|
Phase 1 | |
| Recruiting |
NCT05755932 -
Study to Assess Effect of HFO MDI Propellant on Mucociliary Clearance Compared to HFA MDI Propellant in Healthy Participants
|
Phase 3 | |
| Withdrawn |
NCT01025713 -
A Phase 1 Trial to Assess the Safety, Tolerability, and Pharmacokinetics of GS 9411 in Subjects With Cystic Fibrosis (CF)
|
Phase 1 |